Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc. is a medical technology company that develops and delivers intelligent, rapid, non-invasive testing and screening solutions. The company was formed on December 5, 2016, under the laws of Delaware, along with its wholly owned Delaware subsidiary, GBS Operations Inc. Its Australian subsidiary, Intelligent Bio Solutions (APAC) Pty Ltd, was formed on August 4, 2016, under the laws of New South Wales, Australia. On October 4, 2022, Intelligent Bio Solutions Inc. acquired Intelligent Fingerprinting Limited, a company registered in England and Wales. The company's headquarters are in New York City. Intelligent Bio Solutions Inc. operates globally, aiming to provide innovative and accessible solutions that improve the quality of life. Its current active product is the Intelligent Fingerprinting Platform, a proprietary portable system that analyzes fingerprint sweat. This platform uses a single-use cartridge and a handheld reader. The flagship product from this platform is the Intelligent Fingerprinting Drug Screening System, which is commercially available in certain countries outside of the United States. The Intelligent Fingerprinting Drug Screening System is a non-invasive, fingerprint sweat-based diagnostic screening product designed to detect drugs of abuse. These include opiates, cocaine, methamphetamine, benzodiazepines, cannabis, methadone, and buprenorphine. On December 12, 2025, the company filed a certificate of amendment to effect a 1-for-10 reverse stock split of its common stock, effective 11:59 p.m. December 15, 2025. The common stock began trading on a reverse stock split-adjusted basis on The Nasdaq Capital Market on December 16, 2025.